Irbesartan Aurobindo

Irbesartan, the active ingredient in Irbesartan Aurobindo, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It works by selectively blocking the AT₁ receptor, thereby reducing vasoconstriction and aldosterone release, which helps to lower elevated blood pressure and slow the progression of kidney damage in patients with diabetic nephropathy.

GNH USA supplies Irbesartan Aurobindo as a licensed, GMP‑qualified product sourced from the European Union, providing a GDP‑compliant solution to hospitals, pharmacies and clinics worldwide and health‑care networks.

Irbesartan belongs to the angiotensin II receptor blocker class and is used to manage conditions related to the renin‑angiotensin system.

Hypertension: lowers systolic and diastolic blood pressure in adults. Diabetic nephropathy: slows decline of renal function in patients with type 2 diabetes. Proteinuria in diabetic kidney disease: reduces urinary protein excretion, contributing to renal protection.

Irbesartan is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or weak. - Hyperkalemia: elevated blood potassium detected on laboratory testing.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may compromise breathing. - Severe hypotension: marked drop in blood pressure causing faintness or shock. - Acute renal impairment: sudden worsening of kidney function, indicated by rising creatinine levels.

Before initiating therapy, clinicians should consider several safety measures.

Monitor blood pressure: ensure adequate control without excessive lowering. Assess renal function: check serum creatinine and eGFR at baseline and periodically. Check serum potassium: avoid hyperkalemia, especially when combined with potassium‑sparing agents. Use caution in hepatic impairment: dose adjustments may be required. Pregnancy warning: contraindicated in pregnancy (Category D) due to fetal toxicity. Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Irbesartan may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use can increase risk of renal dysfunction and hyperkalemia. - ACE inhibitors or other ARBs: concurrent therapy may cause excessive potassium rise and renal impairment. - Potassium‑sparing diuretics or supplements: heightened risk of hyperkalemia.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - Thiazide diuretics: additive blood‑pressure lowering, requiring dose titration. - Lithium: irbesartan can raise lithium concentrations, increasing toxicity risk.